Cleared Traditional

MODIFIED SITE MOBILE STAND FOR OPHTHALMIC USE (K883575) - FDA 510(k) Clearance

Class I Ophthalmic device.

K883575 · Site Microsurgical Systems, Inc. · Ophthalmic device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 1988
Decision
21d
Days
Class 1
Risk

K883575 is an FDA 510(k) clearance for the MODIFIED SITE MOBILE STAND FOR OPHTHALMIC USE. Classified as Stand, Instrument, Ophthalmic, Non-powered (product code HMG), Class I - General Controls.

Submitted by Site Microsurgical Systems, Inc. (Horsham, US). The FDA issued a Cleared decision on September 12, 1988 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Ophthalmic FDA review panel, regulated under 21 CFR 886.1860 - the FDA ophthalmic device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Site Microsurgical Systems, Inc. devices

Submission Details

510(k) Number K883575 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 22, 1988
Decision Date September 12, 1988
Days to Decision 21 days
Submission Type Traditional
Review Panel Ophthalmic (OP)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
89d faster than avg
Panel avg: 110d · This submission: 21d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code HMG Stand, Instrument, Ophthalmic, Non-powered
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 886.1860
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.